Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11569029 | 0.90 | MAPT (0.63) | MAPTAPPTSHRABL1POLB | |
| SCHEMBL800531 | 0.88 | MAPT (0.58) | MAPTAPPTSHRABL1POLB | |
| SCHEMBL11047280 | 0.88 | MAPT (0.48) | MAPTABL1POLBRIN1TDP1 | |
| SCHEMBL11568412 | 0.87 | MAPT (0.56) | MAPTAPPTSHRABL1POLB | |
| SCHEMBL780425 | 0.86 | MAPT (0.62) | MAPTAPPTSHRABL1POLB | |
| SCHEMBL13422548 | 0.84 | MAPT (0.53) | MAPTAPPTSHRABL1POLB | |
| SCHEMBL13451568 | 0.83 | MAPT (0.52) | MAPTAPPTSHRABL1POLB | |
| SCHEMBL14000421 | 0.82 | CA12 (0.55) | CA12CA1CA2CA4CA5A | |
| SCHEMBL19690767 | 0.80 | MAPT (0.48) | MAPTTSHROPRD1OPRK1 | |
| SCHEMBL10274478 | 0.79 | CA12 (0.56) | CA12CA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643704-B1 | NEW INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | HAMELN PHARMA GMBH (DE) | 2020-12-16 | — | — | EP | disclosed |
| US-10844014-B2 | Intermediates for the preparation of remifentanil hydrochloride | HAMELN PHARMA GMBH (DE) | 2020-11-24 | — | — | US | disclosed |
| US-10844014-B2 | Intermediates for the preparation of remifentanil hydrochloride | HAMELN PHARMA GMBH (DE) | 2020-11-24 | — | — | US | disclosed |
| US-20200131127-A1 | INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | HAMELN PHARMA PLUS GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| EP-3643704-A1 | NEW INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | hameln pharma plus gmbh (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-8946433-B2 | Process for the preparation of sufentanil base and related compounds | MALLINCKRODT LLC (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2010039260-A2 | SPIPERONE DERIVATIVES AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-1984336-A2 | PROCESS FOR SYNTHESIZING REMIFENTANIL | MALLINCKRODT, INC. (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007087164-A2 | PROCESS FOR SYNTHESIZING REMIFENTANIL | MALLINCKRODT INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844014-B2 | Intermediates for the preparation of remifentanil hydrochloride | OPRK1, OPRM1, OPRD1 | MAPT 1537/4885CA12 3856/4885CA1 1965/4885 |
| US-20200131127-A1 | INTERMEDIATES FOR THE PREPARATION OF REMIFENTANIL HYDROCHLORIDE | OPRK1, OPRM1, OPRD1 | MAPT 1537/4885CA12 3856/4885CA1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.